Fannin in-licenses early-stage therapeutic and medical device technologies from academic investigators in the Texas Medical Center and on a national stage. The company develops and de-risks these technologies via preclinical work and engineering up through early clinical trials.

Fannin Innovation

Fannin is an early-stage life sciences development group focused on commercializing innovation developed in the Texas Medical Center institutions.  Led by an experienced team of managers with diverse business backgrounds, commercialization experience, and strong entrepreneurial knowhow, Fannin partners with promising life science innovators to co-found and actively manage startup companies.  Fannin provides its startups with central office space, seed capital and a vast network of resources. To address the root cause of Houston’s commercialization gap, Fannin works directly with the city’s top-tier, higher education institutions to recruit aspiring entrepreneurs to join its apprenticeship program which provides on-the-job training to collaboratively lead its portfolio companies from innovation to commercialization.

Future Outlook: Fannin has successfully validated this business model over the last seven years and is now in the process of scaling it up.  Another 15-20 portfolio companies are expected to be developed in the next 3 - 5 years.

For more information, email innovate@fannininnovation.com.

Fannin

We are pleased to introduce one of our new summer interns, Deven Narke, to the Fannin team! He is currently a PhD student at Baylor College of Medicine and is researching the role of CYP450 enzymes in lung injury and the microbiome. He holds an MS in Pharmacology & Toxicology from Long Island University, where he published significant research on asthma treatment. He has also contributed to impactful cardiovascular research at NYU Grossman School of Medicine. As the co-founder of TOXINDIA, a preclinical CRO, he has driven substantial company growth and ensured regulatory compliance. He is passionate about strength training, non-fiction literature, and the stock market.   
 
Welcome to the Fannin family, Deven! 
 
#Fannin #Interns #Biotech #LifeSciences #Houston #ExperientialLearning #ProductDevelopment #Mentorship

I planned to share this earlier this month, but was delayed by Hurricane Beryl and its aftermath!

The recent acquisition of Glycotope GmbH by Pentixapharm AG highlights ongoing activity in the field but also presents some unique aspects that may differentiate it  from other recent deals.

At first glance, the fit isn't obvious. Glycotope is an antibody company with multiple programs, none involving radiopharmaceuticals. Pentixapharma is an RLI/RLT company using peptides as its targeting ligand.

Major transactions in the last year have involved late-stage assets with isotope infrastructure, such as Elilill Pharma and Point Therapeutics, Bristol Myers Squibb and RayzeBio, and AstraZeneca and Fusion Pharmaceuticals. 

Others have involved ligand platforms, such as Elilill Pharma and Radionetics Oncology and Aktis Oncology, and Novartis and Mariana Oncology.

What is Pentixapharma gaining? It is acquiring people and infrastructure, though interestingly, not related to radiopharma. It gets a pipeline of antibodies, which could potentially be used to create RLTs, although antibodies may not be the most desirable RLT ligands. However, it also gains a target discovery engine focused on glycoproteins.

As RLT technology matures, novel targets are become increasingly important. Are we going to see target identification platforms as the focus of the next round of acquisitions? Further, does our approach to target selection/validation change with RLTs?

Traditionally, validating the biology of a target has been a critical first step, since most anti-cancer drugs work by modulating cancer biology in some way. This has been true even with ADCs. In contrast, radiopharma works by brute force -- if we deliver the isotope to the cancer, we expect it will be killed.

The path to a clinical imaging/dosimetry trial with a non-therapeutic isotope is relatively rapid and affordable. So rather than in-depth biological validation of a target, could we use patient imaging/dosimetry to validate a target/ligand pair?Further, dosimetry could provide insight into both efficacy (delivery to the tumor) and safety (distribution to normal tissue).

Do RLTs hold the promise of using more predictable physics rather than complex biology for the selection of targets and drugs? If so, that would be a paradigm shift.

Radiomer Therapeutics Fannin
#radiopharmaceuticals #theranostics #radioligandtherapy #rlt #rli #precisionmedicine

Excited about continued progress with the Procyrion, Inc. pivotal #heartfailure clinical trial in patients.  Fannin

We are excited to welcome our new cohort of interns to Fannin next week! These bright minds - Deven Narke, Mason Ruiz, and Kimwai (Robin) Mo Rao - will join us in our mission towards advancing our portfolio of therapeutic technologies closer to the clinic.

At the same time, our thoughts are with the Houston community affected by Hurricane Beryl. We stand in solidarity with those impacted and pray for expedited recovery efforts. 

Stay safe and resilient, Houston!  

#Fannin #Internship #HoustonStrong #HurricaneBeryl #CommunitySupport

Metric
Company Name	Fannin Innovation
Symbol
MSH ID	COM:FANNININNOVATION
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology and Medical Devices
Country	US
Stage
Employee Count	29
Website	fannininnovation.com
LinkedIn	fannin
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

FANN

COM:FANNININNOVATION

Fannin Innovation

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue